<DOC>
	<DOCNO>NCT02191150</DOCNO>
	<brief_summary>The study obtain data show insight clinical outcome patient switch Darbepoetin Alfa epoetin alfa biosimilar .</brief_summary>
	<brief_title>Study Haemodialysis Patients Switching From Aranesp Biosimilar</brief_title>
	<detailed_description>Biosimilars approve 2007 EMA EU 2010 TGA Australia . This study look retrospective data patient switch Darbepoetin Alfa approve epoetin alfa biosimilar . Data collect 26 week period prior switch 26 week period post switch biosimilar . Data collect include haemoglobin measurement , dose requirement , iron use , transfusion , hospitalisation lab value include TSAT , Ferritin albumin . Data study publish .</detailed_description>
	<mesh_term>Darbepoetin alfa</mesh_term>
	<mesh_term>Epoetin Alfa</mesh_term>
	<criteria>Inclusion Criteria Patients â‰¥18 year age Patients CKD haemodialysis fulfil following : Received HD least 26 week prior switch treatment darbepoetin alfa treatment EMA/TGAapproved epoetin alfa biosimilar Received darbepoetin alfa treatment i.v . least 26 week immediately prior switch EMA/TGAapproved epoetin alfa biosimilar ( break due treatment intentionally withhold permit ) Switched darbepoetin alfa treatment EMA/TGAapproved epoetin alfa biosimilar least 26 week prior enrolment Received least one dose EMA/TGAapproved epoetin alfa biosimilar switch darbepoetin alfa treatment Mean monthly Hb 1012g/dL 12 week prior switch Stable darbepoetin alfa dose ( i.e . one increment decrement PFS ) 12 week prior switch Patient patient 's legally acceptable representative provide informed consent , applicable accord local requirement Treatment ESA darbepoetin alfa 12 week prior switch biosimilar More 14 day ' cumulative treatment shortacting ESA week 2613 prior switch biosimilar Subject receive chemotherapy major surgery 26 week prior switch biosimilar Subject enrol interventional device drug study time 52week data observation period within 30 day prior commencement data observation period .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2016</verification_date>
	<keyword>Anaemia , Chronic Kidney Disease , Switching , Aranesp , Darbepoetin Alfa , Epoetin Alfa Biosimilars , Haemodialysis .</keyword>
</DOC>